Literature DB >> 26021725

Rotavirus VP6 preparations as a non-replicating vaccine candidates.

Somayeh Jalilvand1, Sayed Mahdi Marashi1, Zabihollah Shoja2.   

Abstract

Rotavirus (RV) structural proteins VP4 and VP7, located on the surface of viral particles, elicit neutralizing antibodies (Abs) and are therefore considered to be important components of RV vaccines. However, despite inducing neutralizing Abs, limits of cross-neutralizing activity and lack of full correlation with protection limit the usefulness of these proteins as protective agents against RV disease. VP6 protein, which forms the middle layer of RV particles, is discussed as an alternative vaccine candidate since it can induce cross-protective immune responses against different RV strains although the Ab raised is not neutralizing. This report reviews different functions of VP6 that can lead to considering it as an alternative vaccine against RV disease.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Keywords:  Neutralizing; Protection; Rotavirus (RV); VP6

Mesh:

Substances:

Year:  2015        PMID: 26021725     DOI: 10.1016/j.vaccine.2015.05.026

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Rotavirus VP7 epitope chimeric proteins elicit cross-immunoreactivity in guinea pigs.

Authors:  Bingxin Zhao; Xiaoxia Pan; Yumei Teng; Wenyue Xia; Jing Wang; Yuling Wen; Yuanding Chen
Journal:  Virol Sin       Date:  2015-10-10       Impact factor: 4.327

Review 2.  Combined use of lactic-acid-producing bacteria as probiotics and rotavirus vaccine candidates expressing virus-specific proteins.

Authors:  Atefeh Afchangi; Tayebeh Latifi; Somayeh Jalilvand; Sayed Mahdi Marashi; Zabihollah Shoja
Journal:  Arch Virol       Date:  2021-02-03       Impact factor: 2.574

3.  Oral Administration of a Seed-based Bivalent Rotavirus Vaccine Containing VP6 and NSP4 Induces Specific Immune Responses in Mice.

Authors:  Hao Feng; Xin Li; Weibin Song; Mei Duan; Hong Chen; Tao Wang; Jiangli Dong
Journal:  Front Plant Sci       Date:  2017-05-31       Impact factor: 5.753

4.  Performance Evaluation of the Automated Fluorescent Immunoassay System Rotavirus Assay in Clinical Samples.

Authors:  Jae Seok Kim; Su Kyung Lee; Dae Hyun Ko; Jungwon Hyun; Hyun Soo Kim
Journal:  Ann Lab Med       Date:  2019-01       Impact factor: 3.464

5.  Rotavirus VP6 protein mucosally delivered by cell wall-derived particles from Lactococcus lactis induces protection against infection in a murine model.

Authors:  C Facundo Temprana; Marcelo H Argüelles; Nicolás M Gutierrez; Patricia A Barril; Laura E Esteban; Dalila Silvestre; Marcelo G Mandile; Graciela Glikmann; Alejandro A Castello
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

Review 6.  Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials.

Authors:  Zabihollah Shoja; Somayeh Jalilvand; Tayebeh Latifi; Farzin Roohvand
Journal:  Arch Virol       Date:  2022-03-15       Impact factor: 2.685

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.